SMITHKLINE BEECHAM INFANRIX ACELLULAR RECOMMENDED FOR PRIMARY DTP VACCINATION SERIES BY FDA COMMITTEE; MEMBERS CITE LACK OF DATA ON DOSES 4 AND 5
Executive Summary
SmithKline Beecham's Infanrix diphtheria-tetanus-acellular pertussis vaccine was unanimously recommended for approval for the three doses of a primary series of infant vaccination at two, four and six months of age by FDA's Vaccines & Related Biologicals Advisory Committee July 10.